PNGM — Er Therapeutics Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsHighly SpeculativeMicro Cap

Annual income statement for Er Therapeutics, fiscal year end - November 30th, USD millions except per share, conversion factor applied.

	2006 November 30th	2007 November 30th	2008 November 30th	2009 November 30th	2010 November 30th
Period Length:	7 M	12 M	12 M	12 M	12 M
Source:	10KSB	10KSB	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	0	0
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	0.019	0.108	0.139	0.376	0.427
Operating Profit	-0.019	-0.108	-0.139	-0.376	-0.427
Net Income Before Taxes	-0.019	-0.108	-0.139	-0.376	-0.427
Provision for Income Taxes
Net Income After Taxes	-0.019	-0.108	-0.139	-0.376	-0.427
Net Income Before Extraordinary Items
Net Income	-0.019	-0.108	-0.139	-0.376	-0.427
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-0.019	-0.108	-0.139	-0.376	-0.427
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.001	-0.002	-0.003	-0.007	-0.008
Dividends per Share